U
MYGN icon

UBS’s Myriad Genetics MYGN Stock Holding History

UBS’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$4K Sell
100
-12,500
-99% -$466K ﹤0.01% 9625
2014
Q2 		$490K Sell
12,600
-27,000
-68% -$1M ﹤0.01% 4240
2014
Q1 		$1.35M Buy
39,600
+29,500
+292% +$914K ﹤0.01% 3165
2013
Q4 		$212K Sell
10,100
-57,200
-85% -$1.45M ﹤0.01% 5237
2013
Q3 		$1.58M Buy
67,300
+51,700
+331% +$1.47M ﹤0.01% 2844
2013
Q2 		$419K Buy
+15,600
New +$452K ﹤0.01% 4270

Other funds holding MYGN

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

UBS's MYGN Position: Q3 2014 in Review

UBS reduced its Myriad Genetics (MYGN) stake by 9.5% in Q3 2014, selling an estimated $271K and leaving 69,459 shares worth $2.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2634.

UBS first reported a position in MYGN in Q2 2013 and has held it in 6 quarters since. The position peaked at $3.98M in Q4 2013. 275 funds tracked by Wall St. Rank hold MYGN as of Q3 2014.

  • UBS held 69,459 shares of Myriad Genetics worth $2.68M as of Q3 2014.
  • UBS sold 7,273 Myriad Genetics shares in Q3 2014, an estimated $271K.
  • Myriad Genetics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2634 holding.
  • UBS first reported a position in Myriad Genetics in Q2 2013 and has held it in 6 quarters since.
  • UBS's Myriad Genetics position peaked at $3.98M in Q4 2013.
  • 275 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.